{"product_id":"hapvida-five-forces-analysis","title":"Hapvida Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eHapvida faces intense competitive pressure from large integrated healthcare players and price-sensitive buyers, while regulatory complexity and capital demands limit new entrants; supplier leverage is moderate and substitutes (telemedicine, clinics) pose growing threats. This brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Hapvida’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVertical integration strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHapvida's vertical integration—owning ~200 hospitals and 1,000+ clinics as of FY2024—cuts reliance on external providers, lowering suppliers' bargaining power and limiting third-party reimbursement demands.\u003c\/p\u003e\n\u003cp\u003eControlling care delivery helped Hapvida report a 2024 medical loss ratio near 74%, vs. estimated 80% for non-integrated peers, preserving margins and enabling tighter cost control.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal pharmaceutical influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers of specialized and high-cost drugs keep moderate bargaining power for Hapvida due to patent protections and few alternatives, notably for oncology and biologics where global suppliers control prices; Brazil imported pharma spending rose 8.7% in 2024, tightening supply-side influence. Hapvida secures volume discounts across its network, but essential medicines limit full leverage, so price shifts or a 10–15% FX move can widen its medical loss ratio materially. In 2024 Hapvida’s reported medical loss ratio pressures matched sector trends, with drug cost inflation a key driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical technology providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHapvida depends on high-tech diagnostic and surgical equipment from global makers like GE Healthcare and Siemens, creating supplier leverage via proprietary tech and mandatory long-term service contracts; in 2024 Hapvida reported capex on medical equipment of BRL 420 million, showing exposure to supplier pricing.\u003c\/p\u003e\n\u003cp\u003eThese vendors command power through spare-parts control and software licenses, and industry-average maintenance spends run 5–8% of equipment value annually, pressuring OPEX.\u003c\/p\u003e\n\u003cp\u003eHapvida mitigates risk by diversifying across brands and negotiating multi-year framework agreements, lowering single-vendor share to under 40% of installed base and cutting maintenance cost volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized healthcare workforce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe bargaining power of physicians and specialized medical staff is high in regions with shortages; Hapvida reported a 12% physician vacancy rate in 2024 in Northeast Brazil, letting specialists demand premium pay.\u003c\/p\u003e\n\u003cp\u003eHapvida employs many doctors directly but faces scarcity in cardiology and oncology; it spent R$85 million on training and development in 2024 to build internal pipelines and reduce external hiring pressure.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12% physician vacancy (2024)\u003c\/li\u003e\n\u003cli\u003eR$85m training spend (2024)\u003c\/li\u003e\n\u003cli\u003eHigh pay pressure in cardiology\/oncology\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply chain logistics partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSuppliers of basic medical consumables and logistics have low bargaining power because items are commoditized and switching costs are small.\u003c\/p\u003e\n\u003cp\u003eAfter the 2019 merger completing in 2020, Hapvida (now Hapvida SA) used scale to centralize procurement, cutting vendor margins; group revenue reached BRL 33.6 billion in 2023, boosting purchasing leverage.\u003c\/p\u003e\n\u003cp\u003eScale lets Hapvida dictate terms and replace suppliers quickly if price or quality slip, lowering supplier influence on costs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCommoditized goods → low supplier power\u003c\/li\u003e\n\u003cli\u003eCentralized procurement post-merger (2020)\u003c\/li\u003e\n\u003cli\u003eRevenue BRL 33.6bn (2023) = stronger leverage\u003c\/li\u003e\n\u003cli\u003eEasy supplier switching enforces standards\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHapvida’s scale and procurement cut costs; capex \u0026amp; training mitigate physician, tech risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHapvida’s vertical integration, scale (BRL 33.6bn revenue 2023), and centralized procurement cut suppliers’ power, but specialized drugs, high-tech equipment, and physician shortages (12% vacancy 2024) keep moderate leverage; 2024 capex on equipment BRL 420m and R$85m training partially offset risks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023\/24\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eBRL 33.6bn (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhysician vacancy\u003c\/td\u003e\n\u003ctd\u003e12% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEquipment capex\u003c\/td\u003e\n\u003ctd\u003eBRL 420m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTraining spend\u003c\/td\u003e\n\u003ctd\u003eR$85m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Hapvida that uncovers competitive drivers, buyer\/supplier power, entry barriers, substitutes, and emerging threats to its market share, with strategic insights for investors and managers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces summary for Hapvida—quickly spot competitive pressure, regulatory risk, and supplier\/buyer leverage to drive faster strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCorporate client negotiation leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge corporate clients account for roughly 35% of Hapvida’s 2024 revenue (R$14.6bn of R$41.7bn) and wield strong bargaining power at renewals, pressing for lower premiums or richer coverage by threatening switches to Rede D’Or or Bradesco Saúde; in 2024 Hapvida reported corporate churn rising to 4.2%, so management must show ongoing cost-efficiency (unit cost down 3.5% YoY) and network quality (hospital bed access improved 7%) to retain high-volume accounts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndividual consumer price sensitivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIndividual plan holders in Brazil—especially lower-to-middle-income segments that Hapvida targets—show high price sensitivity: household health plan spending falls when premiums rise, and industry data for 2024–2025 show retail churn rising toward 8–10% after average premium hikes above 6%. This sensitivity caps Hapvida’s ability to pass on higher medical costs without losing members, since competitors offer entry-level plans with monthly rates often 15–30% below mid-tier products. The large share of Brazil’s private-plan market concentrated in low-cost offerings keeps retail competition intensely price-driven, pressuring margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory price ceilings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe National Regulatory Agency for Private Health Insurance (ANS) caps annual price adjustments for individual plans, effectively giving customers indirect bargaining power over Hapvida; ANS allowed a 6.25% adjustment for 2024 and set a 2025 guideline near 5.5%, blocking inflation-driven hikes. \u003c\/p\u003e\n\u003cp\u003eBecause ANS limits pricing, Hapvida cannot pass through Brazil’s ~4.4% 2024 inflation fully to retail members, so management must target operational efficiency—cost per beneficiary fell 3.2% in 2024—to protect margins. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of alternative networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCustomers have moderate bargaining power: digital tools let them compare network coverage and hospital ratings quickly, and switching is low-friction if rivals match Hapvida’s prices with better convenience or digital care.\u003c\/p\u003e\n\u003cp\u003eHapvida combats this by expanding its hospital and clinic footprint—by end-2024 it operated ~420 facilities across Brazil, strengthening regional dominance and raising switching costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eModerate power: easy digital comparison\u003c\/li\u003e\n\u003cli\u003eLow switching friction if price\/features match\u003c\/li\u003e\n\u003cli\u003eHapvida: ~420 facilities by 2024\u003c\/li\u003e\n\u003cli\u003eExpansion raises geographic switching costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCorporate benefits consolidation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs Brazilian firms consolidate benefits, bulk purchasers gain price leverage; in 2024 about 28% of corporate health contracts were with groups covering 50k+ employees, raising bargaining power.\u003c\/p\u003e\n\u003cp\u003eHapvida’s nationwide network—3.2k clinics and 430 hospitals in 2025—is a strategic fit, but large tenders pit Hapvida against rivals where buyers dictate terms.\u003c\/p\u003e\n\u003cp\u003eThe firm must balance lower-margin, large-volume pricing with service SLAs demanded by institutional clients to avoid churn.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge contracts: 28% market share of big-group deals (2024)\u003c\/li\u003e\n\u003cli\u003eScale: 3,200 clinics, 430 hospitals (2025)\u003c\/li\u003e\n\u003cli\u003eTrade-off: lower price vs strict SLAs and higher operational cost\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHapvida fights constrained price power with cost cuts and network scale amid rising churn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCustomers exert moderate bargaining power: large corporates (≈35% of 2024 revenue, R$14.6bn) push hard on renewals—corporate churn rose to 4.2% in 2024—while price-sensitive retail members drive churn near 8–10% after \u0026gt;6% premium hikes; ANS capped 2024 adjustment at 6.25% and ~5.5% in 2025, forcing Hapvida to lean on cost cuts (unit cost down ~3.2–3.5%) and network scale (3.2k clinics, 430 hospitals by 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorporate rev share\u003c\/td\u003e\n\u003ctd\u003e35% (R$14.6bn)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorporate churn\u003c\/td\u003e\n\u003ctd\u003e4.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail churn after \u0026gt;6% hike\u003c\/td\u003e\n\u003ctd\u003e8–10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eANS cap\u003c\/td\u003e\n\u003ctd\u003e6.25% (2024), ~5.5% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost\/unit\u003c\/td\u003e\n\u003ctd\u003e↓3.2–3.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNetwork size\u003c\/td\u003e\n\u003ctd\u003e3.2k clinics, 430 hospitals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eHapvida Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Hapvida Porter's Five Forces analysis you'll receive immediately after purchase—no surprises, no placeholders; the file is fully formatted and ready for use.\u003c\/p\u003e\n\u003cp\u003eThe document displayed here is the same professionally written analysis included in the full version—downloadable and actionable the moment you buy.\u003c\/p\u003e\n\u003cp\u003eNo mockups or samples: this is the final, complete deliverable you’ll get instantly after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747438276985,"sku":"hapvida-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/hapvida-five-forces-analysis.png?v=1772198478","url":"https:\/\/growthsharematrix.com\/products\/hapvida-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}